Zai Lab Ltd (ZLAB NASDAQ) stock market data APIs
$19.9754
-0.06(-0.3%)
as of February 13, 2026
Try our APIs with
free plan!
Zai Lab Ltd Financial Data Overview
Price chart is built with
Anychart
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Prev. Close
19.9754
Open
19.9176
High
20.3967
Low
19.8685
52 wk Range
15.96-44.34
Market Cap
2 245 M
Shares Outstanding
112 M
Revenue
442 M
EPS
-0.33
Beta
0.885
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Zai Lab Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zai Lab Ltd data using free add-ons & libraries
Get Zai Lab Ltd Fundamental Data
Zai Lab Ltd Fundamental data includes:
- Net Revenue: 442 M
- EBITDA: -213 792 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.25
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zai Lab Ltd News
New
Zai Lab Limited's (NASDAQ:ZLAB) Shift From Loss To Profit
We feel now is a pretty good time to analyse Zai Lab Limited's (NASDAQ:ZLAB) business as it appears the company may be on the cusp of a considerable accomplishment. Zai Lab Limited, a biopharmaceutica...
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
- Company to host conference call and webcast on February 26, 2026, at 8:00 a.m. ET (9:00 p.m. HKT) SHANGHAI & CAMBRIDGE, Mass., February 10, 2026--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKE...
China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse.
U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the rivalry? Continue Reading
Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
Asian equities traded in the US as American depositary receipts were trending lower Tuesday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
